Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-α inhibitor therapy. A study of 16 biopsies

American Journal of Dermatopathology

Volumn 32, Issue 6, 2010, Pages 568-573

  Laga, Alvaro C ^a   Vleugels, Ruth A ^a   Qureshi, Abrar A ^a   Velazquez, Elsa F ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

anti TNF; drug reaction; psoriasiform; psoriasis; pustular; skin

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LICHEN PLANUS; LICHENOID ERUPTION; MALE; PLASMA CELL; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; SKIN BIOPSY; SKIN MANIFESTATION;

AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BEHCET SYNDROME; BIOPSY; CROHN DISEASE; EOSINOPHILS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLASMA CELLS; PSORIASIS; SKIN; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77955175528     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3181cb3ff7     Document Type: Article

References (23)

1. Wollina U, Hansel G, Koch A, et al. Tumor necrosis factor-a inhibitor- induced psoriasis or psoriasiform exanthemata. First 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008; 9:1-14.
2. Gottlieb AB. Clinical research helps elucidate the role of tumor necrosis factor alpha (TNF-alpha) in the pathogenesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenetic probes. Lupus. 2003;12:192-196.
3. Winterfield LS, Menter A. Infliximab.Dermatol Ther. 2004;17:409-426.
4. Feldmann M, Maini RN. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med. 2003;9: 1245-1250.
5. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol. 2002;2:364-371.
6. Muller-Ladner U, Alten R, Heiligenhaus A, et al. "TRECID", TNFalpha related chronic inflammatory diseases-a new multiple diseases bridging concept [in German]. Dtsch Med Wochenschr. 2009;134:2132-2136.
7. Collamer AN, Guerrero KT, Henning JS, et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008;59:996-1001.
8. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatol Treat. 2009;10:100-108.
9. Takahashi H, Hashimoto Y, Ishida-Yamamoto A, et al. Psoriasiform and pustular eruption induced by infliximab. J Dermatol. 2007;34:446-472.
10. Goiriz R, Dauden E, Perez-Gala S, et al. Flare and change of psoriasis morphology during the course of treatment with anti-tumor necrosis factor blockers. Clin Exp Dermatol. 2007;32:176-179.
11. Lee HH, Song IH, Friedrich M, et al. Cutaneous side effects in patients with rheumatic diseases during application of tumor necrosis factor-a antagonists. Br J Dermatol. 2007;156:486-491.
12. Kary S, Worm M, Audring H, et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor a antagonists. Ann Rheum Dis. 2006;65:405-407.
13. Michaelsson G, Kajermo U, Michaelsson A, et al. Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumor necrosis factor-a in the normal eccrine sweat duct? Br J Dermatol. 2005;153:1243-1244.
14. Thurber M, Faesel A, Strohlein J, et al. Pustular psoriasis induced by infliximab. J Drugs Dermatol. 2004;3:439-440.
15. Manni E, Barachini P. Psoriasis induced by infliximab in a patient suffering from Crohns disease. Int J Immunopathol Pharmacol. 2009;22: 841-844.
16. Rallis E, Korfitis C, Stavropoulou E, et al. Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: a 'class effect' of TNF-alpha antagonists or simply an anti-psoriatic treatment adverse reaction? J Dermatol Treat. 2009;1:1-3. [Epub ahead of print].
17. Charles P, Elliot MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol. 1999;17:205-214.
18. Taylor PC, Peters AM, Paleolog E, et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum. 2000;43: 38-47.
19. Paleolog EM, Young S, Stark AC, et al. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and inteleulin-1 in rheumatoid arthritis. Arthritis Rheum. 1998;41:1258-1265.
20. Exarchou S, Voulgari P, Markatseli T, et al. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol. 2009;4:1-4.
21. Hu S, Cohen D, Murphy G, et al. Interstitial granulomatous dermatitis in a patient with rheumatoid arthritis on etanercept. Cutis. 2008;81:336-338.
22. Voulgari PV, Markatseli TE, Exarchou SA, et al. Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis. 2008;67: 567-570.
23. Passarini B, Infusino SD, Barbieri E, et al. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy. Dermatology. 2007;215: 295-300.